ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

DCPH Deciphera Pharmaceuticals Inc

15.73
0.55 (3.62%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 883,137
Bid Price 15.25
Ask Price 25.00
News -
Day High 16.17

Low
9.90

52 Week Range

High
17.73

Day Low 15.25
Company Name Stock Ticker Symbol Market Type
Deciphera Pharmaceuticals Inc DCPH NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.55 3.62% 15.73 20:00:00
Open Price Low Price High Price Close Price Prev Close
15.37 15.25 16.17 15.73 15.18
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
7,927 883,137 $ 15.69 $ 13,855,323 - 9.90 - 17.73
Last Trade Time Type Quantity Stock Price Currency
18:44:01 2 $ 16.04 USD

Deciphera Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.27B 80.80M - 163.36M -194.94M -2.41 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Deciphera Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No DCPH Message Board. Create One! See More Posts on DCPH Message Board See More Message Board Posts

Historical DCPH Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week15.8216.1714.7415.23332,670-0.09-0.57%
1 Month17.1217.7314.6515.98530,153-1.39-8.12%
3 Months16.0417.7313.2515.30540,308-0.31-1.93%
6 Months12.6717.739.9013.72632,3333.0624.15%
1 Year14.9617.739.9013.93555,3280.775.15%
3 Years43.3748.276.5114.50843,169-27.64-63.73%
5 Years23.9471.116.5123.30692,676-8.21-34.29%

Deciphera Pharmaceuticals Description

Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.

Your Recent History

Delayed Upgrade Clock